CD19 and lymphoma: Interestingly, loss of BID, together with FADD (Fas associated via death domain) and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), was reported to contribute to resistance of lymphoma cells to CD19 CAR T-cells (55).